Navigation Links
B. Braun Large Volume Heparin Infusion Solutions Now Available
Date:7/12/2010

BETHLEHEM, Pa., July 12 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun) announced today the availability of large volume heparin infusion solutions.

(Logo:  http://photos.prnewswire.com/prnh/20081022/NYW008LOGO )

(Logo:  http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO )

Based on the new United States Pharmacopeia (USP) standards for heparin products released by the U.S. Food and Drug Administration (FDA) in October 2009, changes to B. Braun's large volume heparin IV solutions include a modification of the reference standard for the drug's unit dose.

The following heparin infusion solutions are now available from B. Braun without restriction:

  • P5671, Heparin Sodium (40 U/mL) in 5% Dextrose Injection (500 mL EXCEL® Plastic Container)
  • P5771, Heparin Sodium (50 U/mL) in 5% Dextrose Injection (500 mL EXCEL® Plastic Container)
  • P5872, Heparin Sodium (100 U/mL) in 5% Dextrose Injection (250 mL EXCEL® Plastic Container)

In addition, the following heparin infusion solutions remain available on allocation:

  • P8721, Heparin Sodium (2 U/mL) in 0.9% Sodium Chloride Injection (500 mL EXCEL® Plastic Container)

Customer Service (800-227-2862) and Clinical & Technical Support (800-854-6851) teams are available to answer any questions related to availability or product use.

About B. Braun

B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company's "Sharing Expertise®" philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.

Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals. For more information, call 800-227-2862, email us at inquiry.us@bbraun.com or visit B. Braun at www.bbraunusa.com.


'/>"/>
SOURCE B. Braun Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. B. Braun Medical Inc. to Demonstrate Infusion Systems Technologies at HIMSS 2009 Interoperability Showcase
2. B. Braun Awarded Contract With HealthTrust Purchasing Group to Provide Pain Management Solutions
3. B. Braun and Amerinet Sign to Expand Infusion Therapy Offerings
4. MEDRAD and B. Braun Melsungen AG Collaborate to Promote Breakthrough Medical Treatment for Cardiovascular Disease
5. B. Braun Introduces WHIN(R) Safe Huber Needle
6. B. Braun Infusion Systems Complete Interoperability Test for HIMSS10 Interoperability Showcase
7. B. Braun Renal Therapies Division Announces Availability of Adimea
8. FDA Approves Cefepime for Use In B. Brauns DUPLEX(R) System
9. Health Robotics Re-Acquires CytoCares European Rights from B. Braun Melsungen AG for Undisclosed Consideration
10. New Technology Center Increases B. Brauns Infusion Pump Capacity
11. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 Allergy Diagnostics Market: Scope and ... that are used to determine the presence of ... drugs etc. in the samples by determining the ... The report on global allergy diagnostics market, analyzes ... The report consists of an executive summary that ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Dec. 8, 2016  Valeant Pharmaceuticals International, Inc. ... ("Valeant") today announced positive results from a Phase ... assess the safety and efficacy of IDP-118 (halobetasol ... plaque psoriasis. Within the Phase ... to severe psoriasis, IDP-118 showed statistical significance to ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, the game-changing dual ... opening of the Sober College Robert Pfeifer Memorial Learning Center at its location ... was attended by an overwhelming amount of alumni, family, colleagues and friends of ...
(Date:12/9/2016)... ... ... "I had a terrible time trying to get my grandson to use his ... had a more child-friendly design, then children would be more likely to look forward ... avoid the need to deliver medication via a nebulizer mask. The design will not ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Company LLC, announced the first national #QuackGivesBack campaign which supported local breast ... was our first franchise-wide Quack Gives Back initiative, and we’re very ...
(Date:12/8/2016)... ... 08, 2016 , ... With the increasing demand for dental implants, the National ... campaign to inform dentists and patients about the safety issues related to dental restorations. ... in the U.S. is projected to reach $6.4 billion in 2018 with more than ...
(Date:12/8/2016)... N.J. (PRWEB) , ... December 08, 2016 , ... ... delivery technologies and development solutions for drugs, biologics and consumer health products, today ... PSCI was set up in 2006 as a non-profit organization to unite pharmaceutical ...
Breaking Medicine News(10 mins):